RAPH (Raphael Pharmaceutical) Debt-to-Asset : 12.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RAPH Raphael Pharmaceutical Inc RAPH
24 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical Debt-to-Asset?

Raphael Pharmaceutical RAPH 24 Debt-to-Asset is 12.33 as of Mar. 2026. GuruFocus rates RAPH with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Raphael Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.04 Mil. Raphael Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Raphael Pharmaceutical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $0.00 Mil. Raphael Pharmaceutical's debt to asset for the quarter that ended in Mar. 2026 was 12.33.

Raphael Pharmaceutical  (OTCPK:RAPH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Raphael Pharmaceutical Debt-to-Asset Related Terms

Raphael Pharmaceutical Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Raphael Pharmaceutical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Debt-to-Asset Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 1.52 0.64

Raphael Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 1.37 5.86 0.64 12.33

RAPH vs TXMD, AYTU, MRMD: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Raphael Pharmaceutical Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's Debt-to-Asset falls into.


RAPH
24GF Score
Raphael Pharmaceutical Inc RAPH
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raphael Pharmaceutical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Raphael Pharmaceutical's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.034 + 0) / 0.053
=0.64

Raphael Pharmaceutical's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.037 + 0) / 0.003
=12.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 12.33 mean?
Raphael Pharmaceutical (RAPH) has a Debt-to-Asset of 12.33 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's Debt-to-Asset too high?
Raphael Pharmaceutical's current Debt-to-Asset is 12.33. Overall, Raphael Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Debt-to-Asset compare to TXMD and AYTU?
Raphael Pharmaceutical's Debt-to-Asset of 12.33 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Raphael Pharmaceutical and its competitors. Raphael Pharmaceutical's current Debt-to-Asset is 12.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Debt-to-Asset of 12.33. The current Debt-to-Asset is 12.33. Raphael Pharmaceutical's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Debt-to-Asset is 12.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
24GF Score

Get the complete analysis for RAPH

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price